"Innovation + Internationalization" core theme catalyzes, innovative drug ETF Guotai (517110) surges over 2%, with net capital inflows for 4 consecutive days

"Core theme of ‘Innovation + Internationalization’ drives growth. On March 17, the Innovation Drug ETF Guotai (517110) rose over 2%, marking four consecutive days of net capital inflow.

Industrial Securities pointed out that during the 14th Five-Year Plan, China’s strategic planning for new development and accelerating the construction of a Healthy China were emphasized. The biopharmaceutical industry was for the first time given the strategic position of a ‘pillar industry’ in top-level national design. In cultivating and expanding emerging industries, efforts are being made to accelerate the development of strategic emerging industries such as new-generation biopharmaceuticals and support the clinical use of innovative drugs. Regarding strengthening original innovation and tackling key core technologies, the focus on frontier science and technology includes life sciences and biotechnology, major disease prevention and treatment, and innovative drug R&D. ‘Innovation + Internationalization’ remains the core theme of the sector. China’s global competitiveness in innovative drugs continues to strengthen, with ongoing efforts to expand overseas markets and realize commercial profitability. Based on investment and financing data, orders, and performance, the current recovery trend of the innovative drug industry chain is relatively certain.

The Innovation Drug ETF Guotai (517110) tracks the SHS Innovation Drug Index (931409), which selects high-quality companies involved in innovative drug research, biopharmaceuticals, and related fields from the A-share and Hong Kong Stock Connect markets. The constituent stocks feature high R&D investment intensity and innovation capability, reflecting the overall performance of China’s pharmaceutical and biotech industry, especially listed companies related to innovative drugs.

Risk Reminder: Mentioning individual stocks is solely for industry event analysis and does not constitute any stock recommendation or investment advice. Short-term index fluctuations are for reference only and do not predict future performance, nor do they constitute a promise or guarantee of fund performance. Views may change with market conditions and do not constitute investment advice or commitments. Different funds have varying risk and return characteristics; investors should carefully read the fund legal documents, fully understand product features, risk levels, and income distribution principles, and choose products that match their risk tolerance. Invest cautiously.

Daily Economic News

(Edited by: He Chong)

【Disclaimer】This article reflects only the author’s personal views and is not related to Hexun.com. Hexun.com maintains neutrality regarding the statements and opinions in this article and does not provide any explicit or implicit guarantees regarding the accuracy, reliability, or completeness of the content. Readers should only use it as a reference and bear all responsibilities themselves. Email: news_center@staff.hexun.com